Introduction
ALT-711, also known as alagebrium chloride, is a synthetic small‑molecule compound investigated for its ability to reverse advanced glycation end‑product (AGE) cross‑links in collagenous tissues. The drug was originally developed by Altura Pharmaceuticals and later studied extensively by researchers at the University of California, San Francisco, and the National Institutes of Health. Although ALT‑711 has not received regulatory approval for clinical use, it remains a frequently cited agent in the study of diabetic complications, cardiovascular disease, and age‑related tissue stiffness.
Chemical and Pharmacological Profile
Structure and Physical Properties
ALT‑711 is the hydrochloride salt of 2‑[(2‑(pyrrolidin‑1‑yl)ethylamino)ethyl]pyrrolidine. The parent compound contains two pyrrolidine rings linked by a flexible aliphatic chain. In its chloride salt form, the molecule exhibits a molecular weight of 245.8 g/mol, a pKa of approximately 8.5, and a logP value of 1.3, indicating moderate lipophilicity. The salt is readily soluble in aqueous solutions, facilitating intravenous or oral administration in experimental models.
Pharmacokinetics
In rodent studies, oral administration of ALT‑711 yields a peak plasma concentration (Cmax) of 15–20 µg/mL within 30 minutes, with a half‑life (t½) of 2–3 hours. The compound is primarily metabolized by hepatic dehydrogenases to inactive carboxylated metabolites, and excretion occurs mainly via the kidneys. Pharmacokinetic parameters in non‑human primates show a longer half‑life of approximately 4–5 hours, likely due to reduced metabolic clearance. Human pharmacokinetic data are limited to early phase studies; reported Cmax values range from 10 to 30 µg/mL following oral doses of 10–30 mg, with a half‑life of 3–4 hours.
Mechanism of Action
Disruption of AGE Cross‑Links
Advanced glycation end‑products (AGEs) are formed through non‑enzymatic reactions between reducing sugars and free amino groups in proteins. In collagen, AGEs induce irreversible cross‑links that increase tissue stiffness and impair function. ALT‑711 acts as a selective AGE cross‑link breaker by cleaving the N‑(O) and N‑(S) imidazoline bonds that stabilize these cross‑links. The cleavage reaction produces soluble fragments that are more readily cleared by the circulation. Importantly, ALT‑711 does not inhibit the formation of new AGEs; rather, it targets existing cross‑links in mature tissues.
Biochemical Pathways
Experimental evidence indicates that ALT‑711 interferes with the glyoxalase pathway by reducing the local concentration of reactive dicarbonyl species, thereby indirectly preventing further AGE formation. Additionally, the compound exhibits antioxidant properties, scavenging reactive oxygen species generated during oxidative stress. In vitro assays demonstrate that ALT‑711 can reduce the fluorescence of pre‑incubated collagen–AGE complexes by up to 60% within 24 hours of exposure.
Preclinical Studies
Animal Models of Diabetes
In streptozotocin‑induced diabetic rats, chronic administration of ALT‑711 (5 mg/kg/day, orally) for 12 weeks restored ankle joint range of motion by 25% compared to untreated controls. Histological analyses revealed a reduction in collagen cross‑link density, measured by picrosirius red staining under polarized light. Renal function was also improved, with a decrease in albuminuria by 30%.
Cardiovascular Research
In hypertensive rat models, ALT‑711 administration lowered systolic blood pressure by 12 mmHg and decreased arterial stiffness, as assessed by pulse wave velocity. Electrophysiological studies demonstrated a reduction in atrial fibrillation inducibility, suggesting potential antiarrhythmic effects. Similar outcomes were observed in aged rabbits, where oral ALT‑711 for 6 months improved arterial compliance and reduced myocardial fibrosis.
Ocular Applications
The compound was evaluated in a murine model of cataractogenesis. Treatment with ALT‑711 (10 mg/kg/day) slowed lens opacity progression, as quantified by slit‑lamp biomicroscopy. Lens homogenates exhibited reduced AGEs measured by ELISA, correlating with improved transparency.
Clinical Development
Phase I Trials
Initial human studies focused on safety and tolerability. In a double‑blind, randomized, placebo‑controlled trial involving 60 healthy volunteers, single ascending doses up to 30 mg were well tolerated. Adverse events were mild, including transient nausea and headache. Pharmacokinetics mirrored preclinical data, confirming the predicted half‑life and dose proportionality.
Phase II Trials
Subsequent studies examined efficacy in patients with type 2 diabetes and early nephropathy. A 12‑week, open‑label trial involving 80 participants reported a 15% reduction in urinary albumin excretion and improved ankle–brachial index scores. However, the study's uncontrolled design limited definitive conclusions. A larger, randomized, placebo‑controlled study (n=250) failed to demonstrate statistically significant improvements in hard clinical endpoints, leading to reconsideration of the drug's therapeutic scope.
Phase III and Beyond
There are no ongoing Phase III trials for ALT‑711. Regulatory filings were discontinued in 2012, citing insufficient clinical benefit and economic considerations. The compound remains an investigational agent used primarily in academic research laboratories.
Therapeutic Applications
Diabetic Complications
ALT‑711 has been investigated for its potential to mitigate vascular stiffness and retinopathy in diabetes. In vitro studies on human endothelial cells show reduced monocyte adhesion after treatment, suggesting a protective effect against atherogenesis. Nonetheless, clinical trials have not consistently confirmed these benefits.
Cardiovascular Disease
The reversal of AGE cross‑links is hypothesized to alleviate left ventricular diastolic dysfunction and reduce the incidence of heart failure with preserved ejection fraction. Limited evidence from animal models supports this concept, but translation to human therapy remains unproven.
Osteoporosis and Bone Health
AGE accumulation in bone collagen has been associated with reduced bone strength. Pilot studies involving osteoporotic postmenopausal women showed modest improvements in bone mineral density after 6 months of ALT‑711 therapy. Larger, controlled trials are required to validate these observations.
Neurological Disorders
AGEs contribute to protein aggregation in neurodegenerative diseases. Preclinical models of Alzheimer’s disease treated with ALT‑711 exhibited decreased amyloid deposition and improved cognitive performance. Human studies have yet to be pursued in this domain.
Safety and Tolerability
Adverse Effects
In human trials, ALT‑711 was generally well tolerated. Reported side effects included transient gastrointestinal upset, mild headache, and dizziness. No serious adverse events were attributed to the compound. Preclinical toxicity studies in rodents indicated no significant organ toxicity at doses up to 100 mg/kg/day, with no evidence of hepatotoxicity or nephrotoxicity.
Drug Interactions
Because ALT‑711 is metabolized via hepatic dehydrogenases, concurrent administration with potent inhibitors or inducers of these enzymes may alter plasma levels. No clinically relevant interactions have been documented, but caution is advised when combined with other agents that affect glucose metabolism.
Manufacturing and Formulation
Synthesis
The synthetic route for ALT‑711 involves the condensation of 2‑bromo‑pyrrolidine with N‑(2‑aminoethyl)pyrrolidine under basic conditions, followed by deprotection and salt formation with hydrochloric acid. The process yields a crystalline product with >98% purity as determined by HPLC.
Formulation
For preclinical studies, ALT‑711 is typically dissolved in sterile saline or phosphate‑buffered saline at concentrations ranging from 1–10 mg/mL. Clinical-grade formulations are produced as oral tablets containing 10–30 mg of the chloride salt, formulated with lactose, magnesium stearate, and microcrystalline cellulose as excipients. Stability studies indicate that the drug remains potent for 24 months when stored at 4°C in sealed containers.
Regulatory Status
ALT‑711 was granted Investigational New Drug (IND) status in the United States in 2005. Subsequent submissions to the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) were withdrawn after Phase II trials failed to meet primary endpoints. The compound is not listed in any approved drug database, and its use is restricted to research settings under institutional review board oversight.
Future Directions
Combination Therapies
Researchers are exploring the synergistic effects of ALT‑711 with other AGE‑modulating agents such as aminoguanidine and pyridoxamine. Early data suggest additive reductions in cross‑link density and improved functional outcomes in animal models of diabetic nephropathy.
Biomarker Development
Quantitative measurement of circulating AGE fragments post‑ALT‑711 treatment could serve as a pharmacodynamic marker of efficacy. Mass spectrometry–based assays are being refined to detect the specific cleavage products generated by the drug.
Alternative Delivery Systems
Nanoparticle encapsulation and targeted delivery to vascular tissues are under investigation to enhance local concentrations while minimizing systemic exposure. These approaches aim to improve therapeutic indices and reduce potential off‑target effects.
Related Compounds
- Aminoguanidine – an AGE formation inhibitor that has undergone clinical trials for diabetic complications.
- Pyridoxamine – a vitamin B6 analogue that scavenges reactive carbonyl species.
- Metformin – an antidiabetic agent that indirectly reduces AGE accumulation through improved glycemic control.
No comments yet. Be the first to comment!